Arbutus Biopharma Corp (NASDAQ:ABUS)
| 1.90 Delayed Data As of Nov 29 |  +0.05 / +2.70%Today’s Change | 1.69 Today|||52-Week Range 3.15 | -18.45% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $311.9M |
Company Description
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Contact Information
Arbutus Biopharma Corp. 701 Veterans Circle Warminster Pennsylvania 18974 |
Employees
Shareholders
| Other institutional | 31.06% |
| Individual stakeholders | 12.15% |
| Mutual fund holders | 12.02% |
Top Executives
| William H. Collier | President, Chief Executive Officer & Director |
| Michael J. McElhaugh | Chief Operating Officer |
| David C. Hastings | Chief Financial & Accounting Officer |
| Michael J. Sofia | Chief Scientific Officer |
| Karen Sims | Chief Medical Officer |
